Notably, TfRMAb-TNFR does not alter the plasma metabolic panel (Additional file 10: Fig. S9) and weight and locomotion (Additional file 13: Fig. S10A, and D-E and Additional file 11) in the 3xTg-AD mice, and hematology profile in the APP/PS1 [24] and PS19 [26] mice after chronic dosing. This evidence concerns the gene PSEN1 and Alzheimer disease.